NIH-backed research reveals diabetics taking metformin have a lower risk of developing long COVID or dying after infection compared to those on other diabetes medications.
RT’s Three Key Takeaways:
- Metformin Reduces Risk of Long COVID in Diabetics: A large NIH-backed study found that people with type 2 diabetes taking metformin had a 13% to 21% lower risk of developing long COVID or dying after infection compared to those on other diabetes medications.
- Potential for Broader Use in Long COVID Prevention: The findings build on earlier research suggesting metformin may reduce the risk of long COVID in non-diabetic individuals, raising the possibility that the drug could be effective in preventing long COVID more broadly.
- Unclear Mechanisms, but Promising Results: While the exact mechanism by which metformin helps prevent long COVID is unclear, researchers speculate it may reduce inflammation, decrease viral levels, and suppress disease-related proteins.
Adults who use the prescription drug metformin to treat their type 2 diabetes have a lower risk of developing long COVID or dying after a COVID-19 infection than people with diabetes who take other anti-diabetes medications, according to a large study supported by the National Institutes of Health (NIH).Â
The findings, published in Diabetes Care, were based on health data from millions of US patients and could have broader implications for use of metformin in long COVID prevention generally. The study is part of the NIH-funded Researching COVID to Enhance Recovery (NIH RECOVER) initiative.
An earlier NIH-supported clinical trial in 2023 showed that treatment with metformin, commonly used to help control blood sugar, reduced the risk of long COVID by as much as 40% in nearly 1,300 US adults with overweight or obesity, most of whom did not have diabetes. To see if the drug had a similar effect in people with diabetes, researchers examined electronic health record data for nearly 38 million Americans from two large US databases.
Comparing Health Records
The researchers compared health records from 75,996 adults taking metformin for their type 2 diabetes to 13,336 records from patients who were not taking metformin but were using other types of diabetes medicines. Researchers were specifically looking at how many patients either died or were diagnosed with long COVID within six months after infection. They found that patients taking metformin had a 13% to 21% lower incidence of long COVID or death than those in the non-metformin group.
Scientists are not clear how metformin may prevent long COVID, but they speculate the possibility of several mechanisms that reduce inflammation, decrease viral levels, and suppress the formation of disease-related proteins.
Metformin can have side effects and should be used with caution in some conditions. For these and other reasons, people should not take the drug unless prescribed by a doctor.
Long COVID is marked by a wide range of symptoms—including chronic fatigue, brain fog, and chest pain – that vary from person to person and can last for weeks, months, or years after infection from SARS-CoV-2, the virus that causes COVID-19. While rates of new cases have decreased since early in the COVID-19 pandemic, millions of people are still living with it.
ID 81675916 © Sherry Young | Dreamstime.com
